Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 501–600 of 2,053
Dharmalingam, M., Sharma, S. K., Prakash, V., Maiti, A., Kumar, R., Murthy, L. S. S., Balamurugan, R., Maheshwari, S., Kethavath, S. N., Ogale, D., et al. (2024) · Cureus · doi:10.7759/cureus.58115 · Cited by 9
ELUCIDATE Trial: A Single‐Center Randomized Controlled Study
Lin, J., Liu, S.-C., Liu, T., Chuang, S., Huang, C., Chen, Y.-J., Lee, C., Chien, M.-N., Hou, C. J., Yeh, H., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033832 · Cited by 10
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01334-8 · Cited by 8
“Additionally, while SGLT2Is and GLP1As have positive cardiovascular and renal effects, insulin has a neutral effect in this respect, but has a high risk of hypoglycemia and weight gain [4, 5, 7].”
BackgroundRosenstock, J., BAJAJ, H. S., Lingvay, I., & Heller, S. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003930 · Cited by 12
RECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15652 · Cited by 11
“…Improving Global Outcomes and American Diabetes Association clinical practice guidelines recommend that SGLT2 inhibitors be administered first to T2D patients with CKD. 17,18 Switching to GLP-1RA or combination therapy is considered when SGLT2 inhibitors are unavailable or weight loss is promoted.”
Mohammedi, K., Fauchier, L., Quignot, N., Khachatryan, A., Banon, T., Kapnang, R., Kikuchi, K., Ren, H., Massien, C., Vigié, L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02257-4 · Cited by 10
“In people with established cardiovascular disease or at high risk for cardiovascular disease, GLP-1 RA and SGLT2i have been recommended by the consensus reports of the ADA and the EASD since 2018 [36].”
BackgroundKamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Bhattacharya, S., Singla, R., & Kalra, S. (2024) · Medicine · doi:10.1097/md.0000000000038568 · Cited by 10
“[3] 2,4–6] GLP-1RAs may also help prevent renal complications of T2D.”
BackgroundRemission of type 2 diabetes: position statement of the Italian society of diabetes (SID)
Capoccia, D., Leonetti, F., Natali, A., Tricò, D., Perrini, S., Sbraccia, P., Guglielmi, V., & On behalf of the Italian Society of Diabetes (SID) (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02317-x · Cited by 11
“In addition to identifying a specific HbA1c target for each patient, it is recommended to choose the most appropriate drug based on their comorbidities, taking into account the evidence of cardiovascular and renal benefits of some drug classes regardless of their effect on glycemia [73].”
BackgroundCaballero Mateos, I., García de Lucas, M. D., Doulatram-Gamgaram, V. K., Moreno-Moreno, P., Jimenez-Millan, A. I., Botana-López, M., Merino-Torres, J. F., Soto-Gónzalez, A., Fernández-García, J. C., & Morales-Portillo, C. (2024) · Nutrients · doi:10.3390/nu16152545 · Cited by 8
“…on the Management of Hyperglycemia in T2DM by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends GLP-1 RAs as second-line therapy for the treatment of T2DM because of their organ protection benefits beyond improving glycemic control [4].”
BackgroundJi, X., Wang, Y., & Qi, B. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12890 · Cited by 8
Ha, K. H., Shin, S., Na, E., & Kim, D. J. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14363 · Cited by 9
“Furthermore, in the 2021 guidelines of the Korean Diabetes Association, the threshold for prescribing SGLT2is in individuals with an eGFR below 60 mL/min/1.73 m 2 was revised to 30 mL/min/1.73 m 28 .”
InfluentialGaredow, A. W., Tesfaye, G. T., Tamrat, R., & Wynendaele, E. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01795-y · Cited by 13
Alum, E. U., Krishnamoorthy, R., Gatasheh, M. K., Subbarayan, S., Vijayalakshmi, P., & Uti, D. E. (2024) · Natural Product Communications · doi:10.1177/1934578x241299279 · Cited by 23
“15 Insulin therapy has been a treatment option in the management of CKD in T2DM.”
Murasheva, A., Fuks, O., Тимкина, Н. В., Mikhailova, A., Vlasov, T. D., Samochernykh, K. A., & Каронова, Т. Л. (2024) · Biomedicines · doi:10.3390/biomedicines12122797 · Cited by 8
Thomsen, C. H. N., Kronborg, T., Hangaard, S., Vestergaard, P., & Jensen, M. H. (2025) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2024.105783 · Cited by 13
Simone, E. D., Pozzato, M., Marchisio, M., Quattrocchio, G., Zoppo, M., Gervasi, L., & Roccatello, D. (2025) · Scientific Reports · doi:10.1038/s41598-025-87624-1 · Cited by 8
“It is suggested in cases of lactatemia between 15 and 20 mmol/L and pH 7–7.1.”
InfluentialSTOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 11
“While there are key differences, the indications for treatment with each drug often overlap, such as for people with cardiovascular disease or chronic kidney disease [14].”
Kurevija, T., Šojat, D., Bilić-Čurčić, I., Canecki-Varžić, S., & Majnarić, L. T. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02837-7 · Cited by 9
“Achieving target HbA1c levels is thought to reduce adverse clinical outcomes and is used to guide medication therapy [2].”
InfluentialPushpanathan, K., Bai, Y., Lei, X., Goh, J. H. L., Xue, C. C., Yew, S. M. E., Chee, M.-L., Quek, T. C., Peng, Q., Soh, Z. D., et al. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00412-9 · Cited by 11
“The per-sonalised element involves tailoring management strategies to individual patient profiles, accounting for factors such as comorbidities, genetic predisposition, and lifestyle influences [13, 14].”
Xiao, Z., Li, Q., Guo, X., Long, G., Meng, Z., & Xu, C. Y. (2025) · Environmental Research · doi:10.1016/j.envres.2025.122197 · Cited by 9
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
“Table 4 lists the agents currently available in the USA and their dosing strategies [19, 38, 55–58].”
Çelik, Ö., Yazıcı, D., Ciudin, A., Macut, D., Micić, D., Yumuk, V., & Yıldız, B. O. (2025) · Obesity Facts · doi:10.1159/000547055 · Cited by 14
Vilsbøll, T., Malecki, M. T., Sharma, P., Thieu, V. T., Chivukula, K. K., & Kiljanski, J. I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16592 · Cited by 12
Luo, Y., Jiang, H., Shi, B., Cai, H., Wang, H., Li, S., Qiu, W., Li, Y., Zhou, R., Deng, H., et al. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108150 · Cited by 10
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD
Singh, A. K., Anker, S. D., Pitt, B., Rossing, P. R., Ruilope, L. M., Ahlers, C., Farag, Y. M. K., Lambelet, M., BRINKER, M. D., Rohwedder, K., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.10.032 · Cited by 15
Self-citationde Carvalho, F. S., Marques, F. D. B., Lopes, A. E., Ferreira, J. L., & Príncipe, R. M. (2023) · Cureus · doi:10.7759/cureus.33509 · Cited by 11
Ho, L.-J., Sheu, W. H., Lo, S.-H., Yeh, Y., Hwu, C., Huang, C., Hsieh, C., & Kuo, F.-C. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01018-9 · Cited by 12
Nomoto, H. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.188 · Cited by 9
Rowlands, A. V., van Hees, V. T., Dawkins, N. P., Maylor, B. D., Plekhanova, T., Henson, J. J., Edwardson, C. L., Brady, E. M., Hall, A. P., Davies, M. J., et al. (2023) · Sensors · doi:10.3390/s23125382 · Cited by 10
“A strength of this analysis was the large sample of adults with type 2 diabetes, in which sleep and physical activity are compromised but important for health [4,5].”
BackgroundSelf-citationYu, J., Sweeting, A., Gianacas, C., Houston, L., Lee, V. Y., Fletcher, R. A., Perkovic, V., Li, Q., Neuen, B. L., Berwanger, O. B., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15267 · Cited by 8
“…guidelines now recommend the use of SGLT2 inhibitors in adults with T2D at high risk for cardiovascular disease, heart failure, and/or CKD. 7 While the increasing prevalence of obesity has contributed to the global rise in T2D, there is significant heterogeneity with respect to body…”
BackgroundMody, R., Meyer, K. L., Ward, J. M., & O’Day, K. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01470-w · Cited by 10
Dietary guidelines in diabetes – why are they so difficult to follow?
Sińska, B. I., & Kucharska, A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.132024 · Cited by 9
“It may fall within wide ranges: carbohydrates 40–50%, fats 25–40%, proteins 15–25% of energy from the diet [3–6].”
BackgroundJohansson, K. S., Bülow, C., Jimenez‐Solem, E., Petersen, T. S., & Christensen, M. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00210-6 · Cited by 13
Brockmeyer, M., Parco, C., Vargas, K. G., Westenfeld, R., Jung, C., Kelm, M., Roden, M., Akbulut, C., Schlesinger, S., Wolff, G., et al. (2024) · Journal of Nephrology · doi:10.1007/s40620-023-01858-8 · Cited by 9
Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
Yang, Y. P., Pan, X., & Chen, S. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s456336 · Cited by 8
“75 Combination treatment of empagliflozin and semaglutide may offer additional cardiovascular protection in patients with type 2 diabetes.”
BackgroundPractical strategies to manage obesity in type 2 diabetes
Rodbard, H. W., Barnard-Kelly, K. D., Pfeiffer, A. F. H., Mauersberger, C., Schnell, O., & Giorgino, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15556 · Cited by 10
Mingrone, G., & Rajagopalan, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111651 · Cited by 10
Self-citationDavies, M. J., Bodicoat, D. H., Brennan, A., Dixon, S., Eborall, H., Glab, A., Gray, L. J., Hadjiconstantinou, M., Huddlestone, L., Hudson, N., et al. (2024) · BMC Family Practice · doi:10.1186/s12875-024-02372-x · Cited by 9
Self-citationGLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?
Hayat, J., Shah, N. P., Agarwala, A., Khan, M. S., & Butler, J. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01214-6 · Cited by 11
Colacci, M., Raissi, A., Biering‐Sørensen, T., Gyenes, M., Hodzic-Santor, B. H., Manzoor, S., Skaarup, K. G., Moggridge, J. A., Raudanskis, A., Sarma, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307581 · Cited by 8
Johannes, C. B., ZIEMIECKI, R. M., Pladevall, M., Ebert, N., Kovesdy, C. P., Thomsen, R. W., Baak, B. N., García‐Sempere, A., Kanegae, H., Coleman, C. I., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01671-x · Cited by 9
“SGLT2i can be added to other glucose‑lowering drugs (GLDs), and updated guidelines are currently recommending SGLT2i for patients with an estimated glomerular filtra‑ tion rate (eGFR) ≥ 20 ml/min/1.73 m 2 [13–15].”
InfluentialTsunemi, A., Sato, J., Sugimoto, S., Iwagaki, Y., Enomoto, M., Someya, Y., Kiya, M., Matsuhashi, E., Wakabayashi, Y., Funayama, T., et al. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4558 · Cited by 10
Hu, S., Lin, C., Cai, X., Li, Z., Lv, F., Yang, W., & Ji, L. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101868 · Cited by 11
Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review
Teague, M., Martinez, A., Walker, E., El-Rifai, M., & Carris, N. W. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.003 · Cited by 8
Tong, Y.-T., Gao, G.-J., Chang, H., Wu, X., & Li, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1216182 · Cited by 9
Koufakis, T., Zografou, I., Doumas, M. N., & Kotsa, K. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00610-8 · Cited by 10
“%) in young patients with a long life expectancy, provided that this can be achieved without a significant risk of hypoglycemia [4].”
BackgroundEsteghamati, A., Zamanzadeh, M., Malek, M., Khaledi, M., MONAVVARI, A., Najafi, L., Banazadeh, Z., Malboosbaf, R., Aghili, R., Mahdikhah, S., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01462-w · Cited by 9
“Compared with insulin, GLP-1 receptor agonists promote weight loss and are associated with a lower risk of hypoglycemia risk as well as cardiovascular benefits [17, 18].”
BackgroundDecreased Alu methylation in type 2 diabetes mellitus patients increases HbA1c levels
Thongsroy, J., & Mutirangura, A. (2023) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24966 · Cited by 10
Cohen, B., Harris, Y., & Schulman‐Rosenbaum, R. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.014 · Cited by 8
Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons
Koufakis, T., Popovic, D. S., & Παπάνας, Ν. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2237414 · Cited by 10
“For the reasons mentioned above, the most recent guidelines for the management of hyperglycemia in T2D [4] advocate the use of new agents in a large proportion of patients, even before”
BackgroundGiorgino, F., Guerci, B., Füchtenbusch, M., Lebrec, J., Boye, K., Orsini Federici, M., Heitmann, E., Dib, A., Yu, M., Sapin, H., et al. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15244 · Cited by 7
Thomas, S., Besecker, B. Y., Choe, Y. S., & Christofides, E. (2024) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1399410 · Cited by 8
Chen, A. X., Fletcher, R., Neuen, B. L., Neal, B. C., & Arnott, C. G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15751 · Cited by 12
“Current T2D guidelines recommend that SGLT2 inhibitors be considered as a first-line treatment option with metformin in all patients with T2D and comorbid atherosclerotic CV disease or CKD. 16,18,49,50 Recognizing the significant mortality, CV and CKD benefits of SGLT2 inhibitors, T2D treatment guidelines have also mo…”
InfluentialRecent and Upcoming Therapies for Management of Type 2 Diabetes: A Review
Gokalani, R. A., Saiyed, M., Dey, A. K., & Sheikh, F. (2024) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_12_24 · Cited by 8
Tian, C., Yang, Z. R., Zhao, S., Zhang, P., & Li, R. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.09.028 · Cited by 11
Krishnan, S., Srivastava, P. K., Attaluri, J., Nayeri, R., Chatterjee, D., Patel, J., Nsair, A., Budoff, M. J., & Nayeri, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12010019 · Cited by 13
Gulati, K., Wijndaele, K., Webb, J., von Arx, L., Seif, M., Jennison, T., Geneidat, A., Wild, R., Wood, R. P., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16201 · Cited by 9
Almahmeed, W. A., Al-Abadla, Z., Alawadi, F., Alrohmaihi, D., Alshamiri, M. Q., Elbadawi, H., El‐Tamimi, H., Elzouki, A.-N. Y., Farghaly, M., Hafidh, K., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03103-5 · Cited by 10
“C, until targets are reached [57, 106, 108, 111].”
InfluentialBergenstal, R. M., Ásbjörnsdóttir, B., Bari, T. J., Hulkund, S., Winhofer, Y., & Wysham, C. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0050 · Cited by 11
Review of the potential value of treatment targets in obesity management
Almohaileb, F. I., & le Roux, C. W. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2516522 · Cited by 8
“However, this may be impractical in the era of advanced pharmacotherapy for obesity, as some agents improve glycemia independently of weight loss [14].”
Cowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
“3,43,44 These non-insulin medications should include a GLP-1 RA first given the advantages to weight loss and low hypoglycaemia risk vs. starting injectable antihyperglycemic therapy with basal insulin.”
InfluentialXie, X., Yang, J., Ding, C., Li, Y., Al-Smadi, F., Zha, K., Lin, C., Lin, Z., Yu, C., Zeng, R., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.07.025 · Cited by 12
“Diabetes mellitus (DM), a chronic metabolic disorder marked primarily by persistent hyperglycemia [1], presents escalating global health challenges.”
Chakravarthy, M. V., Elliott, M. A., Acosta, L., Sonnenberg, G. E., Bialonczyk, D., Wu, J., ARGÜELLES-TELLO, F. A., Garcia‐Reza, R., González‐González, J. G., Hansen, S. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70006 · Cited by 11
Sørensen, K. K., Yazdanfard, P. D. W., Zareini, B., Pedersen‐Bjergaard, U., Kosjerina, V., Andersen, M. P., Munch, A., Ohlendorff, J. S., Schmid, S., Lanzinger, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02915-1 · Cited by 9
“Also, the guidelines for treatment have evolved during the study period [35].”
Wade, F. G., Lentine, K. L., Turk, D., Kirbach, K., Knobloch, T., Schnitzler, M. A., Qureshi, K., Syn, W., & Fleetwood, V. A. (2025) · Clinical Transplantation · doi:10.1111/ctr.70344 · Cited by 9
“In recent years, semaglutide, a GLP-1 RA, has emerged as a highly effective therapy for weight loss and glycemic control [1, 17].”
Lin, L., Wu, J., Jeng, W., Tsai, C., Sun, J., Kuo, C., Yuliani, F. S., & Lin, S. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70087 · Cited by 10
“13 Specifically, SGLT-2 inhibitors are known to have cardioprotective and renoprotective effects 14 ; GLP-1 receptor agonists provide benefits in atherosclerotic cardiovascular disease and promote weight loss, 15 whereas DPP-4 inhibitors, although weight-neutral, remain a viable option for patients…”
Updates on Anti-Obesity Medications in Children and Adolescents
Salama, M., Hassan, D., & Kumar, S. (2025) · Children · doi:10.3390/children12101390 · Cited by 12
“Tirzepatide, a dual GIP/GLP-1 receptor agonist, is approved for obesity and type 2 diabetes in adults [93,94].”
Guo, L., Dong, X., Ma, J., Liu, M., Lu, Y., Wang, H., Li, Q., Li, L., Deng, Y., & Xu, J. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00248-7 · Cited by 11
Optimizing cardiovascular pharmacotherapy in older adults with frailty
Nguyen, T. N., Woodward, M., Butt, J. H., McMurray, J. J. V., Lip, G. Y. H., & Kaski, J. C. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01244-w · Cited by 9
“A 2022 consensus report from the ADA/European Association for the Study of Diabetes emphasized the importance of considering frailty in the management of T2DM in older adults 73 .”
Zhu, D., Wang, W., Tong, G., Ma, J., WEN, B., Zheng, X., Shi, B., Shuguang, P., Wang, K., Shi, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68165-7 · Cited by 9
Yang, J., Xie, B., Deng, Z., Zhang, Z., & Zhou, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1749826 · Cited by 10
Koufakis, T., Kokkinos, A. D., & le Roux, C. W. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70723 · Cited by 9
“We now understand that excessive sugar intake may contribute to weight gain and metabolic risk, but type 2 diabetes is not caused by a single dietary component, nor is it treated simply by reducing sugar intake alone [34, 35].”
Miyoshi, H., Matsuhisa, M., Yabe, D., Takahashi, Y., Morimoto, Y., & Terauchi, Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01373-w · Cited by 8
“H. Miyoshi Department of Immunology and Metabolism, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan e-mail: hmiyoshi@med.hokudai.ac.jp M. Matsuhisa Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan e-mail:…”
BackgroundInfluentialShabnam, S., Gillies, C., Davies, M. J., DEX, T. A., Melson, E., Khunti, K., Webb, D. R., Zaccardi, F., & Seidu, S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110888 · Cited by 7
Self-citationPrameswari, A. S., Kalanjati, V. P., Yuliawati, T. H., Abdurachman, & Miftahussurur, M. (2023) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2024.01.002 · Cited by 8
The Cardiac-Kidney-Liver (CKL) syndrome: the “real entity” of type 2 diabetes mellitus
Katsiki, N., Kolovou, G. D., Melidonis, A. J., & Banach, M. (2024) · Archives of Medical Science · doi:10.5114/aoms/183070 · Cited by 11
Dubey, V. P., Kansagra, J. J., Sureja, V. P., & Kheni, D. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00603-7 · Cited by 8
“The American Diabetes Association (ADA) and European Association for the Study of Dia - betes (EASD) recommend a patient-centred approach to diabetes care, which includes individualized treatment plans based on patient medical condition and preference [14].”
BackgroundKurevija, T., Šojat, D., Bosnić, Z., Mujaj, B., Canecki-Varžić, S., & Majnarić, L. T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061617 · Cited by 9
“…the 2022 ADA/EASD guidelines focus on the social determinants of health and healthcare systems and provide the necessary evidence for counseling patients on non-pharmacological treatment and behavior changes, including physical activity, sleep hygiene, weight management and nutrition [19].”
BackgroundDiabetes and Stroke: Impact of Novel Therapies for the Treatment of Type 2 Diabetes Mellitus
Vieira, I. H., Carvalho, T., Saraiva, J. C., Gomes, L., & Paiva, I. (2024) · Biomedicines · doi:10.3390/biomedicines12051102 · Cited by 9
“In this context, in 2022, the ADA and the EASD published a new consensus in which they recommend that drugs such as SGLT2is and GLP1-Ra can be used as first-line therapies in patients with established or high risk for CVD, independently of the background use of metformin [25].”
BackgroundMethodInfluentialAnson, M., Malik, A. I., Zhao, S. S., Austin, P. J., Hernández, G., Jaffar, S. S., Garrib, A. V., Cuthbertson, D. J., & Alam, U. (2024) · Journal of Diabetes Research · doi:10.1155/2024/3470654 · Cited by 11
“Sodium-glu-cose-linked-cotransporter-2 inhibitors (SGLT2is) o ff er car-diorenal protection, but early adoption is only encouraged with the presence of concomitant atherosclerotic cardiovascular disease (ASCVD) or chronic kidney disease (CKD) [9].”
BackgroundHypoglycemic Drugs in Patients with Diabetes Mellitus and Heart Failure: A Narrative Review
Nikolaidou, A., Ventoulis, I., Karakoulidis, G., Anastasiou, V., Daios, S., Papadopoulos, S.-F., Didagelos, M., Parissis, J., Karamitsos, T. D., Kotsa, K., et al. (2024) · Medicina · doi:10.3390/medicina60060912 · Cited by 10
“Of note, other glucose-lowering agents with proven CV benefits should be preferred if adequate glycemic control could be achieved without insulin [7,42].”
BackgroundInfluentialLecomte, J., de Beeck, I. O., Mamouris, P., Mathieu, C., & Goderis, G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.002 · Cited by 7
Self-citationAlão, S., Silva, T., Leite, A. P., do Rosário, M., Carvalho, C., Coelho, J., Ferreira, H. J., Ferreira, R., Abreu, J., Rosa, M., et al. (2024) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2024.04.011 · Cited by 9
Wang, F., Li, C., Cui, L., Gu, S., Zhao, J., & Wang, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1436217 · Cited by 11
“This fi nding eventually caused SGLT2i was recommended by the American Diabetes Association and the European Association for the Study of Diabetes for the treatment of high-risk type 2 diabetes patients who suffer from arteriosclerotic cardiovascular disease (64).”
BackgroundWang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae322 · Cited by 10
Self-citationArutyunov, G. P., Drapkina, O. M., Kobalava, Z. D., Конради, А. О., Lopatin, Y. M., Nedogoda, S. V., Sychev, D. A., Ткачева, О. Н., Shestakova, M. V., Shlyakhto, E. V., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6074 · Cited by 8
Alodhialah, A. M., Almutairi, A. A., & Almutairi, M. (2024) · Healthcare · doi:10.3390/healthcare12222257 · Cited by 12
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Kaya, E., Syn, W., & Manka, P. P. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001083 · Cited by 7
Golub, I. S., Manubolu, V. S., Aldana-Bitar, J., Dahal, S., Verghese, D., Alalawi, L. H., Krishnan, S., Kianoush, S., Benzing, T., Ichikawa, K., et al. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104036 · Cited by 12
Do, D., Lee, T., Peasah, S. K., Inneh, A., Patel, U. B., & Good, C. B. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.5.520 · Cited by 13
Oyeka, C. P., He, J. H., Ma, J., Michos, E. D., Kalyani, R. R., Woodward, M., Vaidya, D. M., & Bennett, W. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf287 · Cited by 8
Kiçaj, E., Saliaj, A., Çerçizaj, R., Prifti, V., Qirko, S., & Rogozea, L. M. (2025) · Nursing Reports · doi:10.3390/nursrep15060201 · Cited by 10
“Understanding self-care behaviors, quality of life, and clinical factors is essential for managing diabetes [13]; by mapping these relationships, our findings could offer new insights to enhance the early management of diabetes in Albania.”
Dixit, S., & Tiwari, S. (2020) · Pharmacognosy Journal · doi:10.5530/pj.2020.12.243 · Cited by 9
Chan, S. P., Lim, L., Chan, J. C. N., & Matthews, D. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01386-5 · Cited by 10
“agonist is recommended, while an SGLT2 inhibitor is recommended for those with CKD or heart failure, independent of metformin use and HbA1c at baseline [14, 51].”
BackgroundInfluentialAvgerinos, I., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15200 · Cited by 8
Burden and Coping Strategies of Hypoglycemia in People with Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., Τσάπας, Α., & Bekiari, E. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998271244231010100747 · Cited by 7
Araújo, R. L., Neto, J. X., Fulco, U. L., et al. (2023) · Chemical Physics Letters · doi:10.1016/j.cplett.2023.140934 · Cited by 7
Graue, M., Igland, J., Haugstvedt, A., Hernar, I., Birkeland, K. I., Zoffmann, V., Richards, D. A., & Kolltveit, B. H. (2023) · PLoS ONE · doi:10.1371/journal.pone.0291255 · Cited by 9
“Greater attention to weight management as part of a holistic approach to diabetes self-management is more emphasized now than earlier [3].”
BackgroundInfluentialKiconco, R., Lumumba, S. A., Bagenda, C. N., Atwine, R., Ndarubweine, J., & Rugera, S. P. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241232280 · Cited by 10
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.